Overview
- Indian Institute of Technology Bhubaneswar, the Institute of Life Sciences, and the National Research Development Corporation signed a quadripartite license with TechInvention Lifecare in Bhubaneswar.
- 'HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis' is the candidate transferred for product development and future commercialization.
- The research was led by Prof. Ashis Biswas at IIT Bhubaneswar and Dr. Sunil Kumar Raghav at ILS, with NRDC evaluating the technology and brokering the deal.
- TechInvention will advance the candidate through development and validation, with no clinical-trial or regulatory milestones reported in the announcements.
- The institutes frame the effort against WHO data showing 1.23 million TB deaths in 2024 and the limits of BCG protection for adolescents and adults.